COMMUNIQUÉS West-GlobeNewswire

Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
14/04/2026
— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally [...]
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
14/04/2026
Launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) ( [...]
Extendicare Announces Closing of $450 Million Inaugural Offering of Investment Grade Senior Unsecured Notes
14/04/2026
Not for distribution to U.S. news wire services or dissemination in the United States. MARKHAM, Ontario, April 14, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“ Extendicare ” or the “ Company ”) (TSX: EXE) announced [...]
R1 Announces Revenue Performance Solutions Powered by Phare OS to Help Providers Navigate Growing Complexity and Margin Pressure
14/04/2026
Latest Solutions Focus on Improving AR Recovery and Denials Management CHICAGO, April 14, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced the launch of [...]
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
14/04/2026
SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will [...]
Prenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One
14/04/2026
Partnership Extends IM8’s Mission Beyond Premium Nutrition to Address Malnutrition Among the World’s Most Vulnerable Populations Long-Term Goal to Impact Millions of Lives Through Sustained Funding and Awareness Vitamin [...]
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
14/04/2026
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE [...]
Nextech Reduces Healthcare’s Payment Reconciliation Burden with Reimagined Embedded Payment Processing Platform
14/04/2026
Nextech Payments, Powered by Stripe and Integrated with Affirm, Saves Medical Practices Hours Weekly Through Real-Time Automation TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Nextech, an award-winning technology [...]
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
14/04/2026
TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will [...]
Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline
14/04/2026
Establishes framework targeting multi-product commercialization across high-growth health and wellness categories with scalable revenue potential Woodland, CA, April 14, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: [...]
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
14/04/2026
DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“ [...]
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
14/04/2026
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27) [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
14/04/2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
14/04/2026
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026 QUVIVIQ® is approved through Taiwan’s Streamlined Review [...]
Greenwich LifeSciences Provides Update on Financing Strategy
14/04/2026
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
14/04/2026
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that triggers a personalized [...]
Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma
14/04/2026
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling access to accelerated and rolling review FDA clearance of IND [...]
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique
14/04/2026
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat médicament, PTI5803, [...]
Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
14/04/2026
MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors CAMBRIDGE, United Kingdom, April 14, 2026 (GLOBE [...]

Pages